Drugs / NLY01
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT03672604 Comparator | Sep 2018 → Jul 2019 | — | Neuraly, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT07497399 Comparator | Apr 2026 → Jan 2030 expected | multiple sclerosis | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 2 | NCT04154072 Comparator | Feb 2020 → Feb 2023 | Parkinson disease | Neuraly, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04159766 Comparator | Oct 2019 → Dec 2020 | type 2 diabetes mellitus | Neuraly, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NLY01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07497399 ↗ |
| Known as | exenatide | “NLY01-a brain-penetrant, pegylated, longer-lasting version of exenatide (a glucagon-like peptide-1 receptor agonist)” PMID 38101901 ↗ Jan 20242“NLY01, a PEGylated form of the anti-diabetic peptide exenatide” NCT04159766 ↗ “NLY01 is a pegylated exenatide” NCT07497399 ↗ |
| Modality | Peptide | “anti-diabetic peptide exenatide” NCT03672604 ↗ |
| Route | Subcutaneous | “10 mg subcutaneous weekly” NCT07497399 ↗ |